BioWorld Science: The Daily Drug R&D News Source

Cancer progression pathway and possible therapy for Fanconi anemia identified
Results from a French study of a cohort of individuals with the inherited rare disease Fanconi anemia shed light on how some people with this condition go on to develop secondary leukemia. Writing in the Feb. 2, 2023, issue of Cell Stem Cell, the authors also described some initial tests on cell lines in a mouse model of a drug that has potential to treat individuals with Fanconi anemia who progress to leukemia.

IL-2RG blockade as a therapeutic strategy for prevention and treatment of T-cell-mediated disease
The interleukin-2 receptor subunit γ (IL-2RG), also known as γc cytokine receptor or CD132, family of cytokines includes interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21. These γc cytokines exert broad pleiotropic effects on the innate and adaptive immune system, and they all share the IL-2RG chain as part of its signaling receptor complex. Researchers from Regeneron Pharmaceuticals Inc. aimed to assess whether targeting γc cytokines may serve as a strategy for the prevention and treatment of T-cell-mediated disease.

Cancer progression pathway and possible therapy for Fanconi anemia identified
Results from a French study of a cohort of individuals with the inherited rare disease Fanconi anemia shed light on how some people with this condition go on to develop secondary leukemia. Writing in the Feb. 2, 2023, issue of Cell Stem Cell, the authors also described some initial tests on cell lines in a mouse model of a drug that has potential to treat individuals with Fanconi anemia who progress to leukemia.
IL-2RG blockade as a therapeutic strategy for prevention and treatment of T-cell-mediated disease
The interleukin-2 receptor subunit γ (IL-2RG), also known as γc cytokine receptor or CD132, family of cytokines includes interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21. These γc cytokines exert broad pleiotropic effects on the innate and adaptive immune system, and they all share the IL-2RG chain as part of its signaling receptor complex. Researchers from Regeneron Pharmaceuticals Inc. aimed to assess whether targeting γc cytokines may serve as a strategy for the prevention and treatment of T-cell-mediated disease.
Other news to note for Feb. 3, 2023
Additional early-stage research and drug discovery news in brief.
Discovery of new antileishmanial agents
Researchers from Central Drug Research Institute (CDRI) and the Academy of Scientific & Innovative Research (AcSIR) have synthesized and evaluated a series of novel antileishmanial agents. Synthesis and optimization of a series of halogen-rich salicylanilides led to the discovery of compounds [I] and [II], which demonstrated the best antileishmanial activity, with IC50 values of 2.89 μM and 2.09 μM, respectively against Leishmania donovani amastigote.
Tonix Pharmaceuticals to develop TNX-3900 series of oral antivirals
Tonix Pharmaceuticals Holding Corp. has announced it plans to develop the TNX-3900 series of oral antivirals as monotherapy or in combination with other antivirals, following an agreement whereby it has acquired all of the assets of Healion Bio Inc., including its entire portfolio of next-generation antiviral technology assets.
Xinthera patents new MAPKAPK2 inhibitors
Xinthera Inc. has divulged pyridinones acting as MAP kinase-activated protein kinase 2 (MAPKAPK2) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, fibrosis, metabolic diseases, inflammation and cardiovascular and cerebrovascular disorders.

Today's news in brief

BioWorld

BioWorld MedTech

BioWorld Asia

BioWorld Science

BioWorld Premium